cGMP in the Vasculature.

Barbara Kemp-Harper, Harald H H W Schmidt

Department of Pharmacology, Monash University, Melbourne (Clayton), VIC, 3800, Australia, .

Journal Article: Handbook of experimental pharmacology 02/2009; DOI: 10.1007/978-3-540-68964-5_19

Abstract

Cyclic guanosine 3', 5'-monophosphate (cGMP) plays an integral role in the control of vascular function. Generated from guanylate cyclases in response to the endogenous ligands, nitric oxide (NO) and natriuretic peptides (NPs), cGMP influences a number of vascular cell types and regulates vasomotor tone, endothelial permeability, cell growth and differentiation, as well as platelet and blood cell interactions. Reciprocal regulation of the NO-cGMP and NP-cGMP pathways is evident in the vasculature such that one cGMP generating system may compensate for the dysfunction of the other. Indeed, aberrant cGMP production and/or signalling accompanies many vascular disorders such as hypertension, atherosclerosis, coronary artery disease and diabetic complications. This chapter highlights the main vascular functions of cGMP, its role in disease and the resulting current and potential therapeutic applications. With respect to pulmonary hypertension, heart failure and erectile dysfunction, as well as cGMP signal transduction, the reader is specifically referred to other dedicated chapters.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

aberrant cGMP production
 
blood cell interactions
 
cell growth
 
cGMP signal transduction
 
coronary artery disease
 
Cyclic guanosine 3'
 
dedicated chapters
 
endogenous ligands
 
erectile dysfunction
 
Generated
 
heart failure
 
natriuretic peptides
 
nitric oxide
 
NPs
 
potential therapeutic applications
 
Reciprocal regulation
 
regulates vasomotor tone
 
resulting current
 
vascular cell types